Search
SB-509
go.drugbank.com/drugs/DB05579InvestigationalSB-509 is under investigation in multiple clinical trials for the treatment of Diabetic Neuropathy.
PSN357
go.drugbank.com/drugs/DB05044ExperimentalPSN357 is a glycogen phosphorylase inhibitor (GPI), which is designed to rapidly lower blood glucose levels by preventing glycogen breakdown to glucose in the liver.
Tezacitabine
go.drugbank.com/drugs/DB06433InvestigationalA synthetic purine nucleoside analogue with potential antineoplastic activity.
Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins
go.drugbank.com/drugs/DB15729InvestigationalLipoaspiration, also known as liposuction, is a possible method for extraction. This is followed by purification and expansion of the cells in vitro. … This explains why AMSCs have been utilized in repairing craniofacial bone defects. They also have potential in treatment of scarred vocal folds.
Synonyms: Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic OriginsRGN6024
go.drugbank.com/drugs/DB33059ExperimentalReglagene announced FDA orphan drug designation for glioblastoma in 2024. RGN6024 remains investigational and is not an approved drug. … It is designed as an orally administered, blood-brain barrier penetrant therapy for brain cancers, especially glioblastoma.
Buntanetap
go.drugbank.com/drugs/DB15317InvestigationalBuntanetap (previously known as Posiphen) is under investigation in clinical trial NCT02925650 (Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's Disease).
FINLAY-FR-1
go.drugbank.com/drugs/DB16524ExperimentalFINLAY-FR-1, also known as Soberana 01, is a vaccine candidate for COVID-19 that is being led developmentally by the Finlay Vaccine Institute[L31373]. … , of the prophylactic FINLAY-FR-1 anti-SARS-CoV-2 Vaccine Candidate in a two-doses schedule.
Synonyms: FINLAY-FR-1 anti-SARS-CoV-2 vaccine candidateEdivoxetine
go.drugbank.com/drugs/DB09184InvestigationalEdivoxetine failed to be approved for major depressive disorder after phase III clinical trials in 2012. … Edivoxetine is a drug which acts as a selective norepinephrine reuptake inhibitor and is currently under development by Eli Lilly for attention-deficit hyperactivity disorder (ADHD) and as an antidepressant
EPC2407
go.drugbank.com/drugs/DB05189InvestigationalIt is intended for the treatment of advanced cancer patients with solid tumors that are well vascularized. … EPC2407 is a novel small molecule vascular disruption agent and apoptosis inducer for the treatment of patients with advanced solid tumors and lymphomas.
1,4-Dithiothreitol
go.drugbank.com/drugs/DB04447ExperimentalA reagent commonly used in biochemical studies as a protective agent to prevent the oxidation of SH (thiol) groups and for reducing disulphides to dithiols. [PubChem]